VADoDDrugClassReviewTemplate.docVIP

VA/DoD Drug Class Review: Luteinizing Hormone Releasing Hormone (LHRH) Agonists in Prostate Cancer Update November 2007 and June 2010 Department of Defense Pharmacoeconomic Center (DoD PEC) Department of Veterans Affairs Pharmacy Benefits Management Service (VA PBM) and the VA Medical Advisory Panel (VA MAP) Introduction The purpose of this review is to assess the efficacy, safety, and administration of the LHRH agonists currently available in 1, 3, 4, 6 or 12-month preparations for the treatment of prostate cancer. This review will also define selection criteria for contracting of these agen